Long-term cellular immunity of vaccines for Zaire Ebola Virus Diseases

Long-term cellular immunity of vaccines for Zaire Ebola Virus Diseases

Abstract Recent Ebola outbreaks underscore the importance of continuous prevention and disease control efforts. Authorized vaccines include Merck’s Ervebo (rVSV-ZEBOV) and Johnson & Johnson’s two-dose combination (Ad26.ZEBOV/MVA-BN-Filo). Here, in a five-year follow-up of the PREVAC randomized t...

Full description

Saved in:
Bibliographic Details
Main Authors: Aurélie Wiedemann, Edouard Lhomme, Mélanie Huchon, Emile Foucat, Marion Bérerd-Camara, Lydia Guillaumat, Marcel Yaradouno, Jacqueline Tambalou, Cécile Rodrigues, Alexandre Ribeiro, Abdoul Habib Béavogui, Christine Lacabaratz, Rodolphe Thiébaut, Laura Richert, Yves Lévy, the Prevac study team
Format: Article
Language:English
Published: Nature Portfolio 2024-09-01
Series:Nature Communications
Online Access:https://doi.org/10.1038/s41467-024-51453-z
Tags: Add Tag
No Tags, Be the first to tag this record!

Internet

https://doi.org/10.1038/s41467-024-51453-z

Similar Items